Blockchain Registration Transaction Record

ABVC BioPharma to Invest Over $100 Million in U.S. Operations for Pharmaceutical Manufacturing and Botanical Production

ABVC BioPharma announces plans to invest over $100 million in U.S. operations, focusing on pharmaceutical manufacturing and botanical production. The strategic investment includes acquiring a facility in California and constructing 'gigafactories' to support projected product sales exceeding $100 million annually within five years.

This news matters as ABVC BioPharma's significant investment in the U.S. operations indicates a commitment to delivering high-quality plant-based therapies globally. The establishment of 'gigafactories' and expansion of production capacity not only creates new job opportunities but also aims to enhance product quality and provide a sustainable supply chain for botanical-based pharmaceuticals.